Solaiman, Imbran A.
HRN: 24-45-04 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/09/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/09/2024
07/16/2024
IV
100mg
Q24hours
PCAP-C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes